drugset / Trial / NCT05373680
Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized controlled trial aims at evaluating the efficacy and safety of the antidiabetics metformin versus empagliflozin on chronic kidney disease (CKD) progression in patients with CKD stages 2 or/and 3.
Timeline
- Start
- 2022-01-01
- Primary completion
- 2024-04-01
- Completion
- 2024-04-01
Publications
- Mahboub BM, Refaie AF, El-Haggar SM, Hafez YM, Mostafa TM. Efficacy and safety of metformin versus empagliflozin on chronic kidney disease progression (MET-EMPA-CKD): a randomized controlled trial. Diabetol Metab Syndr. 2025 Dec 10;18(1):17. doi: 10.1186/s13098-025-02040-9.
- El-Damanawi R, Stanley IK, Staatz C, Pascoe EM, Craig JC, Johnson DW, Mallett AJ, Hawley CM, Milanzi E, Hiemstra TF, Viecelli AK. Metformin for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2024 Jun 4;6(6):CD013414. doi: 10.1002/14651858.CD013414.pub2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 10 mg | Oral |
| Subject | Metformin | Small molecule | 1000 mg | Oral |